China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

The National Joint Procurement Office issued the Announcement on the Information Change Work for Selected Products in National Organization of Drug Volume‑Based Procurement, permitting – when selected enterprises and their…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Genentech's Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC
CompanyDrug

Genentech’s Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

HutchMed's Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression
CompanyDrug

HutchMed’s Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

FDA Approves At‑Home Subcutaneous Induction Regimen for AbbVie's Skyrizi (Risankizumab) in Moderately to Severely Active Crohn's Disease – On‑Body Injector Enables Treatment Start at Home
CompanyDrug

FDA Approves At‑Home Subcutaneous Induction Regimen for AbbVie’s Skyrizi (Risankizumab) in Moderately to Severely Active Crohn’s Disease – On‑Body Injector Enables Treatment Start at Home

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes
CompanyDrug

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that its CD30 antibody‑drug conjugate (ADC) Adcetris (generic name: brentuximab vedotin for injection) has been officially approved by China's National Medical Products Administration (NMPA) for use in combination with cyclophosphamide, doxorubicin,…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

CStone's Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC
CompanyDrug

CStone’s Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination
CompanyDrug

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher's 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites
Company

SCIEX Breaks Ground on Beijing Mass Spectrometry Manufacturing Site – Danaher’s 10th Production Facility in China, Making Beijing Its First City Globally with Three Manufacturing Sites

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication
CompanyOthers

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager
CompanyDeals

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inc. (NASDAQ: ZYME) announced that it has entered into an exclusive global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a novel trispecific…

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio
CompanyDeals

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
CompanyDeals

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing
CompanyDeals

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions
Policy / Regulatory

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

More News

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond
CompanyDrug

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access
CompanyDrug

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC
CompanyDrug

ZEGFROVY (sunvozertinib) Officially Launches in the U.S. as Dizal and AstraZeneca Bring First Oral EGFR TKI Option to Pretreated Exon 20 Insertion NSCLC

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry
Company

Ipsen Raises Full‑Year 2026 Guidance as 9M Sales Surge 23.0% to EUR 3.36 Billion – Rare Disease Doubles and Oncology Accelerates Ahead of Somatuline Generic Entry

Sino Biopharm's CTTQ Wins China's First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch
Others

Sino Biopharm’s CTTQ Wins China’s First Generic Approval for TQC3403 Umeclidinium/Vilanterol Inhaler – Head‑to‑Head Phase III Equivalence Backs COPD Maintenance Launch

Harbour BioMed's Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis
CompanyDrug

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

Merck's Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor
CompanyDrug

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Show More